Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Cenicriviroc Mesylate (formerly known as TAK-652 Mesylate or TBR-652 Mesylate) is a novel, orally bioactive, and dual antagonist of CCR2/CCR5, it also inhibits both HIV-1 and HIV-2, and has the potential for the treatment of HIV infection. TAK-652 inhibited the binding of MIP-1beta, macrophage inflammatory protein 1alpha (MIP-1alpha), and RANTES (regulated on activation, normal T-cell expressed and secreted) to CCR5-expressing cells at nanomolar concentrations. Additionally, TAK-652 may prevent monocyte chemotactic protein 1 (MCP-1) from attaching itself to cells that express CCR2b. Its ability to prevent ligand binding to other chemokine receptors was, nevertheless, somewhat restricted. TAK-652 exhibited activity against HIV-1 that used CCR5 (R5), but it was completely inert against HIV-1 that used CXCR4 (X4).
Targets |
CCR5 ( IC50 = 0.29 nM ); CCR2 ( IC50 = 5.9 nM ); R5 HIV-1 ( IC50 = 0.024-0.08 nM ); R5 HIV-2 ( IC50 = 0.03-0.98 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
Cenicriviroc blocks HIV-1 from entering cells at an effective concentration of 50% EC50 of 0.03, 0.33, 0.45, and 0.98 nM for the four R5 HIV-2 clinical isolates that were tested. Cenicriviroc resistance in the dual-tropic and X4-tropic HIV-2 strains is >1000 nM for EC50 and 33% and 4% for MPI, respectively.
|
|
Cell Assay |
Three separate assessments are made ex vivo of mouse monocyte migration in response to Cenicriviroc Mesylate (CVC) treatment. In male C57BL/6 mice (n = 3; 8–10 weeks old), thioglycollate (TG) is injected intraperitoneally. 48 hours later, activated macrophages are extracted through peritoneal lavage. A 1 μM solution of cenicriviroc mesylate is added to the cells and incubated for two hours. Flow cytometry is used to count the number of F4/80+CD11b+ macrophages by analyzing cells extracted from the lower compartment. With FlowJo software, results are analyzed[1].
|
|
Animal Protocol |
|
|
References |
|
Molecular Formula |
C42H56N4O7S2
|
|
---|---|---|
Molecular Weight |
793.05
|
|
Exact Mass |
792.36
|
|
Elemental Analysis |
C, 63.61; H, 7.12; N, 7.06; O, 14.12; S, 8.09
|
|
CAS # |
497223-28-6
|
|
Related CAS # |
Cenicriviroc; 497223-25-3
|
|
Appearance |
Solid powder
|
|
SMILES |
CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C.CS(=O)(=O)O
|
|
InChi Key |
IXPBPUPDRDCRSY-YLZLUMLXSA-N
|
|
InChi Code |
InChI=1S/C41H52N4O4S.CH4O3S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2;1-5(2,3)4/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46);1H3,(H,2,3,4)/b34-26+;/t50-;/m0./s1
|
|
Chemical Name |
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.15 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2610 mL | 6.3048 mL | 12.6095 mL | |
5 mM | 0.2522 mL | 1.2610 mL | 2.5219 mL | |
10 mM | 0.1261 mL | 0.6305 mL | 1.2610 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05630885 | Active Recruiting |
Drug: CVC 150 mg Drug: CVC 300 mg |
HIV-1-infection | National Institute of Allergy and Infectious Diseases (NIAID) |
May 30, 2023 | Phase 2 |
NCT02684799 | Completed | Drug: Cenicriviroc Drug: Omeprazole Drug: Famotidine |
Healthy | Tobira Therapeutics, Inc. | January 31, 2016 | Phase 1 |
NCT02342067 | Completed | Drug: Cenicriviroc Drug: Pioglitazone |
Healthy | Tobira Therapeutics, Inc. | December 2014 | Phase 1 |
NCT02685462 | Completed | Drug: Rosuvastatin Drug: Atorvastatin Drug: Simvastatin Drug: Digoxin Drug: Caffeine |
Healthy | Tobira Therapeutics, Inc. | January 31, 2016 | Phase 1 |
NCT04500418 | Terminated | Drug: Cenicriviroc (CVC) Drug: Placebo |
Covid19 | Charite University, Berlin, Germany |
August 25, 2020 | Phase 2 |
Inhibitory effect of TAK-652 on binding of RANTES (A), MIP-1α (B), and MIP-1β (C) to CCR5.Antimicrob Agents Chemother.2005 Nov;49(11):4584-91. th> |
---|
Inhibitory effect of TAK-652 on ligand binding to various chemokine receptors.CHO cells expressing CCR1 (open circles), CCR2b (open squares), CCR3 (filled triangles), CCR4 (open triangles), or CCR7 (filled circles) were incubated with various concentrations of TAK-652 in binding buffer containing125I-labeled RANTES, MCP-1, eotaxin, TARC, or MIP-3β, respectively. Binding reactions were performed at room temperature and terminated by washing out the cell-free ligand with PBS. The cell-associated radioactivity was measured with a scintillation counter. Data represent means ± standard deviations for triplicate wells.Antimicrob Agents Chemother.2005 Nov;49(11):4584-91. td> |
Antiviral activity of TAK-652 against R5X4 HIV-1 in U87.CD4.CCR5 and U87.CD4.CXCR4 cells. The cells were infected with R5X4 HIV-1 (HE) and incubated in the presence of test compounds (100 nM). After incubation for 6 h, the cells were washed to remove unadsorbed viral particles and further incubated in the presence of the same concentration of the test compounds for 3 days. Plasma concentration-time profiles after single oral administration of TAK-652 to humans.Antimicrob Agents Chemother.2005 Nov;49(11):4584-91. td> |